Mauro Krampera

Docenti di ruolo di Ia fascia

University of Verona
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (25)

Year:

2026

Background/Objectives: Treatment of HIV-associated lymphoma (HIV-Ly) with autologous stem cell transplantation (ASCT) has shown a surprisingly low relapse rate in several series. The aim of this study was to compare the clinical outcomes of HIV-Ly and lymphomas in the general population receiving ASCT. Methods: We compared two series of consecutive HIV-positive and HIV-negative patients, based on a 1:1 propensity score analysis, matching for age, sex, histology, disease status and prior therapies. Results: After propensity matching we identified a final population of 88 patients (44 HIV-positive vs. 44 HIV-negative). All HIV-positive patients received combination antiretroviral therapy (cART). With a median follow-up of 51 months, PFS was significantly higher in HIV-positive patients (4-year PFS 81% and 51%, in HIV-positive and HIV-negative patients, respectively, p = 0.027). Four-year OS was 81% for HIV-positive and 67% in HIV-negative patients (p = 0.15). The relapse rate was significantly higher in HIV-negative patients (36% vs. 23%) (p = 0.04). Conclusions: Our results clearly show that ASCT is an effective curative option for HIV-Ly, with better PFS and a lower relapse rate compared to patients without HIV. A favorable effect of ASCT on HIV infection and immune system recovery, potential off-target effects of cART or other yet unknown factors may account for this observation.

Year:

2026

Year:

2026

Year:

2026

Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization—European Organization of Research and Treatment of Cancer (WHO–EORTC) classification and International Consensus Classification (ICC). including primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), intravascular large B‐cell lymphoma (IVLBCL) and Epstein–Barr virus–positive mucocutaneous ulcer (EBVMCU). These subtypes differ significantly in clinical behavior, histopathological features, molecular alterations, and prognosis. Indolent forms such as PCFCL and PCMZL are typically managed with local therapies and are associated with an excellent prognosis. In contrast, aggressive variants such as PCDLBCL‐LT require systemic treatment and are linked to poorer outcomes. EBVMCU, despite its alarming histological appearance, generally follows a benign and self‐limiting course. This review provides an updated overview of the current diagnostic criteria, clinical management strategies, and emerging molecular insights for each CBCL subtype. It also emphasizes the importance of a multidisciplinary approach and discusses the challenges of prognostication, along with the evolving but still limited role of innovative therapies.

Year:

2026

Year:

2026

Dural-based lymphomas are rare extranodal non-Hodgkin lymphomas that span from indolent primary dural entities, most commonly extranodal marginal zone (mucosa-associated lymphoid tissue) lymphoma, to aggressive variants that are primary or represent secondary involvement from systemic lymphoma. They overlap radiologically with benign meningiomas, dural metastases, and immune-mediated pachymeningitis, creating a risk of anchoring bias, delayed diagnosis, and unnecessarily extensive resections when limited tissue sampling would be sufficient for diagnosis. We conducted a structured narrative review to synthesize the epidemiology, clinico-pathological classification, imaging phenotypes, and management principles of dural lymphomatous disease. This study will especially focus on primary dural lymphoma (PDL) with additional discussion of secondary dural involvement. Emphasis is placed on the clinical value of a multiparametric diagnostic approach that integrates computed tomography contrast-enhanced magnetic resonance imaging with functional techniques, and fluorodeoxyglucose positron emission tomography/computed tomography for systemic staging and for distinguishing truly localized primary dural lymphoma from secondary involvement. Potential diagnostic pitfalls related to somatostatin receptor–based tracer uptake will also be discussed. We introduced a pragmatic operational framework based on four clinico-biological clusters, translated into a step-by-step decision algorithm that prioritizes timely biopsy and comprehensive hematologic staging to guide surgical strategy. Given the absence of dedicated, multidisciplinary guidance for dural-based lymphomas, this algorithm is intended as a reproducible foundation for consensus recommendations and future multicenter validation.

Year:

2026

Acute Myeloid Leukemia is mainly a disease of the elderly: however, the knowledge on the outcomes of treatment in core binding factor AML (CBFAML) in older population, is limited. We retrospectively collected data on 229 patients with CBF- AML followed long-term in the last two decades. A 5-year overall survival (OS) of 44.2% (95%CI, 39.9-47.5) and a 5-year event – free survival (EFS) of 32.9% (95%CI, 25.5-40.1) was observed. In a subgroup of >70-year patients who completed intensive therapy (induction + >3 courses of consolidation including autologous stem cell transplant: 10 patients) the median EFS was 11.8 months (95%CI, 9.4 – 15.2) and OS was 40.0% (95%CI, 36.4 – 44.1) at 5yr. In univariate analysis, age >70 (hazard ratio (HR) 1.78, [95%CI, 1.15 – 2.54], p=.008), failure to achieve remission following induction (HR, 8.96 [95%CI, 5.5 – 13.8], p=<.0001), no consolidation therapy (HR, 0.75 [95%CI, 0.47 – 1.84], p=.04) and less than 3 cycles of consolidation (HR, 1.48 [95%CI, 0.75 – 3.2], p=.0004), predicted poorer EFS. Our study shows that intensive therapy, in selected older CBF-AML patients, leads to longer survival. Achieving a CR seems to be the most important first step and at least 3 cycles of consolidation, an important second one. The analysis suggests that these patients should not be excluded from studies with intensive therapies.

Year:

2025

Background/Objectives: Three-dimensional (3D) in vitro cell culture models have recently stimulated great interest since they may have more pre-clinical value than conventional in vitro 2D models. In fact, 3D culture models may mimic the in vivo biophysical 3D structure of tumors and cell-to-cell interaction, thereby representing a more useful approach to testing drug responses. In this study we have developed a 3D culture model of an EBV+/CD30+cell line, D430B, previously characterized as an Anaplastic Large Cell Lymphoma of B phenotype (B-ALCL), to determine the cytotoxic activity of the antibody–drug conjugate Brentuximab Vedotin. Methods: By using of ultra-low attachment plates, we developed D430B spheroids that appeared particularly homogenous in terms of growth and size. Results: Brentuximab Vedotin treatment (1 to 20 μg/mL) turned out to be significantly cytotoxic to these cells, while the addition of the anti-CD20 chimeric antibody Rituximab (10 μg/mL) appeared almost ineffective, even though these cells express CD20. Moreover, when we co-cultured D430B cells with stromal cells (HS5), to re-create a microenvironment representative of neoplastic cell/mesenchymal cell interactions within the lymph node, we observed a significant, although faint, protective effect. Conclusions: This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients’ primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (47)

Cristina Santoro

Sapienza University of Rome

ITALY
View details

Girolamo Pelaia

Professor of Respiratory Medicine

Magna Graecia University

ITALY
View details

Simona D'Amore

Ricercatori a tempo determinato

University of Bari Aldo Moro

ITALY
View details

Daniela de Totero

Ospedale Policlinico San Martino

ITALY
View details

Armando Santoro

Professore

Humanitas University

ITALY
View details

Angelo Vacca

-

ITALY
View details

Alessandro Re

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

ITALY
View details

Pellegrino Musto

Full Professor of Hematology

University of Bari Aldo Moro

ITALY
View details

Paola ROSSI

Professor

University of Pavia

ITALY
View details

Federica Cavallo

University of Turin

ITALY
View details

Linda Bussini

Assistant Professor

IRCCS Humanitas Research Hospital

ITALY
View details

Monica Bocchia

University of Siena

ITALY
View details

Marco Musso

Ricercatore sanitario

Ospedale Policlinico San Martino

ITALY
View details

Lorenzo Cosmi

Full Professor of Internal Medicine

University of Florence

ITALY
View details

Massimo Massaia

Associate Professor of Hematology

Università degli Studi di Torino

ITALY
View details

Roberto CHIGNOLA

Associate professor

University of Verona

ITALY
View details

John C. Byrd

UPMC Hillman Cancer Center

UNITED STATES
View details

Valerio De Stefano

Full Professor of Hematology

Università Cattolica del Sacro Cuore

ITALY
View details

Massimiliano BONIFACIO

University of Verona

ITALY
View details

Paolo Corradini

Full Professor of Hematology

University of Milan

ITALY
View details

Francesca Palandri

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Gianenrico Senna

Head

University of Verona

ITALY
View details

PIER LUIGI ZINZANI

University of Bologna

ITALY
View details

Alessia Savoldi

Università degli Studi di Torino

ITALY
View details

Alessandra Vultaggio

section of biochemistry university of florence italy

ITALY
View details

Luca Arcaini

Director of Division of Hematology

Fondazione IRCCS Policlinico San Matteo

ITALY
View details

Effrossyni Gkrania-Klotsas

Cambridge University Hospitals NHS Foundation Trust

UNITED KINGDOM
View details

Giuseppe Avvisati

Full Professor of Hematolgy

Università Campus Bio-Medico di Roma

ITALY
View details

Domenico Russo

University of Brescia

ITALY
View details

Federica Sora'

professor

Università Cattolica del Sacro Cuore

ITALY
View details

Paola Parronchi

Associate Professor

University of Florence

ITALY
View details

Marco LADETTO

Associate Professor

Università degli Studi del Piemonte Orientale

ITALY
View details

Patrizia Chiusolo

Università Cattolica del Sacro Cuore

ITALY
View details

Massimo Martino

Director Stem Cell Transplant Program

Azienda ospedaliera "Bianchi-Melacrino-Morelli"

ITALY
View details

Gianluca GAIDANO

Professor of Hematology

-

ITALY
View details

Alessandra Tucci

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

ITALY
View details

Ilaria Mormile

Ricercatori a tempo determinato

Università degli Studi di Napoli Federico II

ITALY
View details

MASSIMO TRIGGIANI

Professor of Medicine

University of Salerno

ITALY
View details

Silva Ljevar

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Mario DI GIOACCHINO

YDA - Institute of Clinical Immunotherapy and advanced Biological treatments

ITALY
View details

Roberta Sommaggio

University of Padua

ITALY
View details

Francesca Wanda Rossi

Associate Professor

University of Naples Federico II

ITALY
View details

Francesco Castelli

Professor of Infectious Diseases

University of Brescia

ITALY
View details

Anna Candoni

Docenti di ruolo di IIa fascia

University of Modena and Reggio Emilia

ITALY
View details

Andrea Visentin

Assistant professor

University of Padua

ITALY
View details

ANNALISA CHIAPPELLA

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Carlo Visco

University of Verona

ITALY
View details